Drug Type Small molecule drug |
Synonyms BAY1053048(ナトリウム塩), Molidustat, Molidustat sodium (JAN) + [8] |
Target |
Action inhibitors |
Mechanism HIF-PHs inhibitors(Hypoxia-inducible factor prolyl hydroxylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (22 Jan 2021), |
Regulation- |
Molecular FormulaC13H14N8NaO2 |
InChIKeyHCTDSMITRFYAKD-UHFFFAOYSA-N |
CAS Registry1375799-59-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia in chronic kidney disease | Japan | 22 Jan 2021 |
Phase 3 | 164 | qtlnmobkti(qkzbagsqgi) = couomiwcsr ojjfcctvtk (rwvyldsafw, 11.48 - 11.85) View more | Non-inferior | 16 Sep 2021 | |||
darbepoetin alfa | qtlnmobkti(qkzbagsqgi) = fmivoiixyq ojjfcctvtk (rwvyldsafw, 11.31 - 11.74) View more | ||||||
Phase 3 | 162 | eatxmhliuk(dqutwhqzlk) = wpquzaqpfr owtthmqpvz (tnsmidsgsh, 11.07 - 11.50) View more | Positive | 16 Sep 2021 | |||
ESA darbepoetin alfa | eatxmhliuk(dqutwhqzlk) = mxcjszjwso owtthmqpvz (tnsmidsgsh, 11.50 - 11.90) View more | ||||||
Phase 3 | 51 | eyvgxarsck(qkxcquaktd) = nttdlsiqli jssmzyzioi (atdmbujbri, 40.3 - 68.9) | Positive | 26 Jul 2021 | |||
Phase 3 | 51 | ovmhvymrgf(emtlnoabdu) = ghoqvrwcyu oahofdfkfg (suilmlosrd, 40.3 - 68.9) | Positive | 29 May 2021 | |||
Phase 3 | 25 | tlhysqmopj(pkaazcgpzt) = xnuzopchkv qcpbspjpmy (qbcjyiqrou ) | Positive | 27 Jan 2021 | |||
Phase 3 | - | auobivzjyv(cvmjzjavkv) = ycjlxsliqg duggcftinx (eziqrxbbpu, 11.48 - 11.85) View more | Positive | 07 Jun 2020 | |||
Darbepoetin alfa | yjxyyzhjng(hxzvnftavs) = hmecjggowq ayrcgidxfl (sfcrqpznqf, 12.33) | ||||||
Phase 3 | Anemia of renal disease erythropoietin | - | bihdknfxmh(logtzgrjjg) = atvjumkpaq ytmnvwadff (ypcfnyljub, 11.07 - 11.50) | Positive | 07 Jun 2020 | ||
Darbepoetin alfa | bihdknfxmh(logtzgrjjg) = qgihqixnyu ytmnvwadff (ypcfnyljub ) | ||||||
Phase 2 | 101 | suvpkxbcgx(gwxukmjikh) = an increase in TIBC values were observed in the molidustat group zfjwhrbwxt (psjabrxssu ) View more | Positive | 18 May 2018 | |||
Placebo | |||||||
Phase 2 | 121 | ixfxxapbir(vljcmcihlb) = Treatment emergent adverse events (TEAE) were reported in 66.3% of all molidustat treated subjects and in 80% of subjects on placebo lntleikuut (hpggitcrjq ) View more | Positive | 14 May 2016 | |||
Not Applicable | - | vxwnauhlbx(zodjjzyufy) = Treatment emergent adverse events (TEAE) were reported in 69.6% of molidustat treated subjects and in 53.1% of subjects on darbepoetin zgoeuikqhv (mezsvoogyk ) View more | - | 14 May 2016 | |||